Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of DZD9008 in EGFR exon 20 insertion-mutated advanced or metastatic non-small cell lung cancer
CTR20211009Phase 2Completed
- Sponsor
- Dizal Pharmaceutical Co., Ltd.
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sunvozertinib in non-small cell lung cancer (NSCLC), sponsored by Dizal Pharmaceutical Co., Ltd. Primary endpoint: Objective response rate. Started Jul 2021; status: completed.
02
Drugs
sunvozertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20211009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211009.